

Johanna Oechtering

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/171992/publications.pdf>

Version: 2024-02-01

21
papers

701
citations

759233

12
h-index

713466

21
g-index

23
all docs

23
docs citations

23
times ranked

1048
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. <i>Lancet Neurology</i> , The, 2022, 21, 246-257.	10.2	210
2	Gut microbiota-specific IgA B cells traffic to the CNS in active multiple sclerosis. <i>Science Immunology</i> , 2020, 5, .	11.9	132
3	Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 220-231.	3.0	55
4	Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. <i>Journal of Neuroinflammation</i> , 2021, 18, 105.	7.2	44
5	Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis. <i>Neurology</i> , 2019, 93, e1439-e1451.	1.1	43
6	Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. <i>JAMA Neurology</i> , 2022, 79, 682.	9.0	41
7	Monitoring of radiologic disease activity by serum neurofilaments in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	6.0	24
8	Vitamin D supplementation and neurofilament light chain in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2020, 141, 77-80.	2.1	22
9	Association of serum Epstein-Barr nuclear antigen-1 antibodies and intrathecal immunoglobulin synthesis in early multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2015, 285, 156-160.	2.3	21
10	Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 90, 477-489.	5.3	16
11	The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102534.	2.0	14
12	Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis. <i>Brain Communications</i> , 2021, 3, fcab084.	3.3	14
13	Growth differentiation factor 15 is increased in stable MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	6.0	12
14	Acute hydrocephalus due to impaired CSF resorption in Toscana virus meningoencephalitis. <i>Neurology</i> , 2012, 79, 829-831.	1.1	11
15	Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. <i>Journal of Clinical Lipidology</i> , 2020, 14, 675-684.e2.	1.5	8
16	Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS. <i>Annals of Neurology</i> , 2022, 91, 814-820.	5.3	7
17	Xenogeneic Neu5Gc and self-glycan Neu5Ac epitopes are potential immune targets in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	6.0	6
18	Spinal cord gray matter atrophy is associated with functional decline in post-polio syndrome. <i>European Journal of Neurology</i> , 2022, 29, 1435-1445.	3.3	6

#	ARTICLE	IF	CITATIONS
19	Impact of complement activation on clinical outcomes in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 944-950.	3.7	4
20	Determination of CSF GFAP, CCN5, and vWF Levels Enhances the Diagnostic Accuracy of Clinically Defined MS From Non-MS Patients With CSF Oligoclonal Bands. <i>Frontiers in Immunology</i> , 2021, 12, 811351.	4.8	4
21	Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	3